Primer Capital
Primer Capital is a venture capital firm based in Moscow, Russia, specializing in early-stage investments in the pharmaceutical and biotechnology sectors. Established in 2015, the firm focuses on promising projects in areas such as oncology, cardiology, rheumatology, and medical devices, among others. Primer Capital typically invests between $0.2 million and $0.5 million and also considers co-investments, collaborating with various stakeholders, including other venture capital funds, business angels, and government agencies interested in the biopharmaceutical industry. The firm benefits from a qualified team and a Scientific Advisory Board made up of experts in medical and biopharmaceutical fields, which aids in the careful selection of projects for its portfolio. Primer Capital's extensive experience and knowledge of the industry ecosystem enhance the prospects for its portfolio companies, supporting them in establishing effective partnerships and facilitating fundraising throughout their development.
Nelo is a financial technology company based in Mexico City, established on April 8, 2019. It specializes in developing a mobile application and a digital payment management platform that enables users to conduct financial transactions effectively. The platform allows individuals to send and request money easily, while also providing a free virtual card with no charges for account opening. This service facilitates real-time payment and balance tracking, empowering users to manage their funds in an affordable and secure manner.
MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients.
Botkin.AI is a Moscow-based software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015, the company focuses on developing advanced tools for healthcare providers to enhance the diagnosis of oncological diseases. Its platform employs deep machine learning to analyze medical images, such as radiograms, and assess the risk of tumors, particularly lung cancer, at early stages with high accuracy. By streamlining the analysis of clinical data, Botkin.AI enables radiologists to diagnose tumors more effectively and efficiently, improving patient outcomes without compromising the quality of medical conclusions.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.
MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients.
Acticor Biotech is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the urgent need for effective therapies in the acute phase of ischemic stroke, a condition that affects approximately 15 million people globally each year, leading to significant mortality and disability. Currently, there is a lack of effective treatment options, with existing therapies demonstrating limited efficacy and accessibility. Acticor Biotech seeks to provide innovative solutions to improve outcomes for stroke patients, addressing a critical gap in current medical care.
The lead asset is the monoclonal antibody based on a proprietary therapeutic platform to target CD71 selectively in the tumor microenvironment. Gemopharm’s approach mitigates potential toxicities that may occur from solicitation of non-selective complement dependent cytotoxicity (CDC) activation or addition of a toxin payload. Gemopharm has generated in vivo proof-of-concept data demonstrating substantial efficacy and validating the mechanism of action of the lead candidate. The pilot toxicology has been completed without any signs of toxicity (no mortalities, clinical signs, or DLTs observed). Gemopharm envisages that its lead candidate can address a high unmet need for effective therapies for relapsed/refractory primary and secondary central nervous system (CNS) and intraocular lymphomas (IOL).
MT-Medicals developed a highly specific inhibitor of cytochrome P450 enzymes that demonstrate high conservation, which greatly reduces the probability of tuberculosis bacterial resistance to the new treatment. Its use significantly optimizes the existing combined treatment regimens for resistant forms of tuberculosis and supports the individualization of such treatment. MT-Medicals is based in Hefei City, Anhui Province, China.
Bendit is a medical company focused on the development and manufacturing of innovative catheters that utilize a unique bending technology, allowing for enhanced steering capabilities in both micro diameter and traditional catheter designs. The company specializes in creating microcatheter devices that facilitate optimal navigation within the body, particularly in challenging anatomical areas. Bendit's products are designed to improve procedural efficiency by enabling healthcare professionals to reach target sites with fewer tools, thereby reducing risks and increasing the likelihood of successful outcomes. The organization is a joint venture comprising three experienced groups that bring expertise in production, quality and regulation, and medical development.
Botkin.AI is a Moscow-based software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015, the company focuses on developing advanced tools for healthcare providers to enhance the diagnosis of oncological diseases. Its platform employs deep machine learning to analyze medical images, such as radiograms, and assess the risk of tumors, particularly lung cancer, at early stages with high accuracy. By streamlining the analysis of clinical data, Botkin.AI enables radiologists to diagnose tumors more effectively and efficiently, improving patient outcomes without compromising the quality of medical conclusions.
Data MATRIX Ltd. is a data management and biostatistics company based in Saint Petersburg, Russia, founded in 2014. It specializes in providing a comprehensive range of services for clinical trials, including its cloud-based electronic data capture platform, Matrix EDC, which supports various study formats. The company offers tools for patient randomization with Matrix IWRS and clinical trial management through Matrix CTMS. Data MATRIX also emphasizes data verification through both automated and manual methods, ensuring compliance with international and local regulations regarding personal data processing. Additionally, the company provides electronic patient-reported outcomes (ePRO) solutions to enhance data collection accuracy. With a focus on integrating artificial intelligence into its operations, Data MATRIX develops tools that facilitate data cleaning, curation, and validation to support clinical research initiatives effectively.
MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.
FK Laboratoriz
Seed Round in 2016
FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination of computer-based simulation and chemosynthesis, which are modern and recognized methods applied in the pharmaceutical industry.
Solo is a service for personalized anticancer therapy selection.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.